Rather, in line with the findings of others,17, 20 results of our study suggest that a (low‐dose) treatment with 4MP may attenuate the activation of JNK and related signalling pathways and may thereby attenuate liver inflammation in settings of non‐obese MASLD. Here, MAPK8 is linked to metabolic dysfunction-associated steatotic liver disease.